PubMed Health⌕ Search

Biomedical subjects

S A Velichko

Publications and source records attributed to S A Velichko.

36 records · Page 2Linked to original sources
PubMedDate not supplied

[Computed tomography in the evaluation of regional metastases of lung cancer].

The rate of metastatic spread of different groups of intrathoracic lymph nodes has been studied in depending on localization of the tumor by the nodes using CT method. 126 patients were examined with verified diagnosis of lung cancer. The central form was diagnosed in 55 (43.6%) patients, peripheral--in 71 (56.4%), a tumor was located in the upper lobe in 72 (57.1%), in the lower lobe--in 47 (37.4%), and in the middle lobe--in 7 (5.5%). CT-semiotic of metastatic lymph nodes was studied. The indices of the efficiency of diagnostic imaging when using CT were analyzed as well. The analysis of data obtained has shown that CT has great possibilities in evaluation of regional metastases of lung cancer.

Adenocarcinoma↗
PubMedDate not supplied

[Radiologic follow-up and prognosis of efficiency of systemic Sr-89 Cl-2 therapy of bone metastases in prostate cancer].

We evaluated possibilities of bone scintigraphy with 99mTc-methylendiphosphonate (99mTc-MDP) and magnetic resonance imaging (MRI) in follow-up and prediction of effect in patients with extensive bone metastatic disease treated with betha-emitter 89SrCl2. 24 patients with prostate cancer and extensive metastatic involvement of skeleton were referred for the study. 89SrCl2 was injected as single injection of 150 MBq (4 mCi), in eighteen from Amersham plc., England, as Metastron, in six--from Medradiopreparat, Russia). In all patients bone scintigraphy with 99mTc-MDP and MRI study of metastatic regions were performed before and in 3 months after 89SrCl2 injection. Patients treated with Metsatron were also studied in 6 months after injection. Quantitative analysis of data comprised count and anatomic dimensions of metastatic areas and calculation of indices [metastasis/intact bone] both for scintillation count of 99mTc-MDP bone scans and signal intensity of T1-weighted MRI scan. Henceforth, we conclude the data of bone scanning with 99mTc-MDP and of MRI give evidencies for significant regress of bone metastases in patients treated with 89SrCl2 besides symptomatic suppression of pain syndrome. 99mTc-MDP bone scanning is also of predictive value for the prognosis of therapeutic effect of systemic radiotherapy with 89SrCl2 in prostate cancer.

Aged↗
PubMedDate not supplied

[Radiologic diagnosis of bone metastases recurrence in patients with prostate cancer treated strontium-89].

Aiming to evaluate efficiency of 89SrCl (Metastron) in patients with metastatic lesion of the skeleton in prostate cancer we have performed a follow-up scintigraphy of the skeleton with 99mTc-methylendiphosphonate (MDP) and MRI with quantitative study of metastatic foci. 12 patients with prostate cancer (on the average 11 +/- 6 bone metastases were examined using scintigraphy of the skeleton with 99mTc-MDP and MRI study in T1, T2 and proton density modes. Investigations were performed before injected as a single dose of 150 MBq (4 mCi). At all the stages there was made a quantitative study of foci of pathological uptake of 99mTc-MDP compromising numbers of foci, focus parameters, intensity of 99mTc-MDP accumulation in the pathological part relatively the contralateral region as well as quantification of MRI signals from metastatic areas in signal intensity units. In 3 month 4 patients with extensive metastatic skeletal lesion (> 12) showed a considerable decrease of number of foci of pathological 99mTc-MDP uptake (on average to 6 +/- 3). In the remained metastatic foci there was noted a decrease of dimensions and 99mTc-MDP uptake intensity at an average by 29.8 +/- 15%, improvement in T1 intensity by 113 +/- 55.6 units. In 2 patients who initially presented a "superscan" pattern on 99mTc-MDP bone scintigraphy the 89SrCl treatment converted this of low intensity had demonstrated their complete regression. Results of radiologic follow-up of bone metastases in prostate cancer using MRI and bone scintigraphy with 99mTc-MDP argue that systemic radiotherapy with 89SrCl induces significant regress of metastatic process that involves all volume of the metastases.

Bone Neoplasms↗
PubMedDate not supplied

[99m-Tc-Technetryle mammascintigraphy: clinical protocol and first experience in clinical diagnosis of breast cancer].

Analyzing the results of 99mTc-Technetryle mammascintigraphy in 41 females with breast cancer indicated that polypositional planar mammascintigraphy ensures a high sensitivity (over 88%) in revealing a primary nodule in T1, (more than 95%) in large tumors at above 95% specificity. No nodal accumulation of 99mTc-Technetryle was observed in controls (with fibrocystic mastopathy and suspected coronary heart disease. Mammascintigraphy showed a 85% sensitivity in recognizing axillary lymph nodal metastases too and ascertained that 14 patients had suptaclavicular and subclavian lymph nodal metastases. Therefore, 99mTc-technetryle mammascintigraphy is the method of choice in early detecting a tumorous process, primarily lymphogenic metastasis in breast cancer, and in evaluating its extent.

Breast Neoplasms↗